LENTIVEX
LIVE

Serial Number

79359897

Owner

Oxford Genetics Ltd

Attorney

John R. Schaefer

Filing Date

Nov 18, 2022

Add to watchlist:

No watchlists yet
View on USPTO

LENTIVEX Trademark

Serial Number: 79359897 • Registration: 7435355

LENTIVEX is a trademark filed by Oxford Genetics Ltd on November 18, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Oxford Genetics Ltd (12 trademarks)

Medawar Centre,

Entity Type: 99

Trademark Details

Filing Date

November 18, 2022

Registration Date

July 9, 2024

Published for Opposition

April 23, 2024

Goods & Services

Chemical and biological reagents for medical and veterinary use; diagnostic and test reagents for medical and veterinary use; human and animal stem cells for medical and veterinary purposes; preparations of microorganisms for medical and veterinary purposes; viral vectors being tissue cultures for medical and veterinary purposes; lentiviruses, lentivirus particles and lentivirus plasmids for medical and veterinary use being biological preparations for the treatment of cardiovascular, degenerative, dermatological, endocrine, gastrointestinal, genetic, gynaecological, neurological, infectious, immunological, metabolic, oncological, ophthalmic, respiratory and urological disorders and diseases

Chemical and biological preparations for use in science and industry; nucleic acids for laboratory use; nucleic recombinant acids for laboratory use, synthetic deoxyribonucleic acids for laboratory use; chemical and biological reagents for non-medical and non-veterinary purposes; chemical and biological reagents for scientific and research purposes; human and animal stem cells for non-medical and non-veterinary purposes; microorganisms for non-medical purposes being cultures of microorganisms other than for medical and veterinary use; human and animal stem cells for scientific and research purposes; cultures of microorganisms for scientific and research purposes; viral vectors being chemicals and biological preparations for use in science and industry; lentiviruses, lentivirus particles and lentivirus plasmids being chemicals and biological preparations for scientific and research purposes

Product design and development services relating to the creation and alteration of chemical and biological reagents; new product design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids; new product design services relating to the creation and alteration of recombinant viruses; new product design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids; scientific research, product development and bioengineering services relating to lentiviruses; drug discovery services; design services relating to the creation and alteration of cell lines, elementary cells and parts thereof being drug discovery services; design services relating to the creation and alteration of viral vectors being drug discovery services; information and advice relating to all the aforesaid services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 5, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 16, 2024 FICS
FINAL DISPOSITION PROCESSED
Dec 16, 2024 FIMP
NEW REPRESENTATIVE AT IB RECEIVED
Nov 8, 2024 NREP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 9, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 9, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 9, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 30, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 7, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 7, 2024 OPNR
NOTIFICATION PROCESSED BY IB
Apr 30, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 23, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 10, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 10, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 20, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 19, 2024 TROA
REFUSAL PROCESSED BY IB
Oct 11, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 20, 2023 RFCS
REFUSAL PROCESSED BY MPU
Sep 20, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 1, 2023 RFCR
NON-FINAL ACTION WRITTEN
Aug 31, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 31, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 13, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 9, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 6, 2023 REPR